WO2000066144A3 - DOSES MENSUELLES DESTINEES AU TRAITEMENT DES INFECTIONS PAR $i(STREPTOCOCCUS PNEUMONIAE) - Google Patents

DOSES MENSUELLES DESTINEES AU TRAITEMENT DES INFECTIONS PAR $i(STREPTOCOCCUS PNEUMONIAE) Download PDF

Info

Publication number
WO2000066144A3
WO2000066144A3 PCT/US2000/008737 US0008737W WO0066144A3 WO 2000066144 A3 WO2000066144 A3 WO 2000066144A3 US 0008737 W US0008737 W US 0008737W WO 0066144 A3 WO0066144 A3 WO 0066144A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
streptococcus pneumoniae
glycopeptide antibiotics
pneumoniae infections
monthly doses
Prior art date
Application number
PCT/US2000/008737
Other languages
English (en)
Other versions
WO2000066144A2 (fr
Inventor
Thomas Reeves Parr
Margaret Mary Wasilewski
Michel Lee Zeckel
Original Assignee
Lilly Co Eli
Thomas Reeves Parr
Margaret Mary Wasilewski
Michel Lee Zeckel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU43292/00A priority Critical patent/AU774647B2/en
Priority to UA2001117510A priority patent/UA73937C2/uk
Priority to DE60016734T priority patent/DE60016734T2/de
Priority to CA002372790A priority patent/CA2372790A1/fr
Priority to EA200101171A priority patent/EA004295B1/ru
Priority to EP00923113A priority patent/EP1175222B1/fr
Priority to JP2000615028A priority patent/JP2002543146A/ja
Application filed by Lilly Co Eli, Thomas Reeves Parr, Margaret Mary Wasilewski, Michel Lee Zeckel filed Critical Lilly Co Eli
Priority to PL00353444A priority patent/PL353444A1/xx
Priority to IL14558200A priority patent/IL145582A0/xx
Priority to AT00923113T priority patent/ATE284702T1/de
Priority to SK1557-2001A priority patent/SK285970B6/sk
Priority to NZ514467A priority patent/NZ514467A/en
Priority to BR0010244-0A priority patent/BR0010244A/pt
Publication of WO2000066144A2 publication Critical patent/WO2000066144A2/fr
Publication of WO2000066144A3 publication Critical patent/WO2000066144A3/fr
Priority to IL145582A priority patent/IL145582A/en
Priority to NO20015291A priority patent/NO20015291L/no
Priority to HR20010808A priority patent/HRP20010808A2/hr
Priority to HK02104765.3A priority patent/HK1044707B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé de prévention à long terme de S. pneumoniae chez les personnes sensibles, selon lequel on administre à la personne sensible une dose au moins mensuelle de NDISACC-(4-(4-chlorophényl)-benzyl)A82846B, de téicoplanine ou de leur mélange.
PCT/US2000/008737 1999-05-03 2000-04-19 DOSES MENSUELLES DESTINEES AU TRAITEMENT DES INFECTIONS PAR $i(STREPTOCOCCUS PNEUMONIAE) WO2000066144A2 (fr)

Priority Applications (17)

Application Number Priority Date Filing Date Title
BR0010244-0A BR0010244A (pt) 1999-05-03 2000-04-19 Doses mensais para tratamento de infecções por streptococcus pneumoniae
DE60016734T DE60016734T2 (de) 1999-05-03 2000-04-19 Monatliche gaben von glykopeptid-antibiotika zur langzeitprävention von streptokokkus pneumoniae infektionen
CA002372790A CA2372790A1 (fr) 1999-05-03 2000-04-19 Doses mensuelles destinees au traitement des infections par streptococcus pneumoniae
EA200101171A EA004295B1 (ru) 1999-05-03 2000-04-19 Способ лечения инфекций, вызванных streptococcus pneumoniae
EP00923113A EP1175222B1 (fr) 1999-05-03 2000-04-19 Doses mensuelles de glycopeptides antibiotiques pour la prevention de longue duree d'infections par des streptocoques pneumoniae
JP2000615028A JP2002543146A (ja) 1999-05-03 2000-04-19 肺炎レンサ球菌感染症を処置するための月一回投薬
AT00923113T ATE284702T1 (de) 1999-05-03 2000-04-19 Monatliche gaben von glykopeptid-antibiotika zur langzeitprävention von streptokokkus pneumoniae infektionen
PL00353444A PL353444A1 (en) 1999-05-03 2000-04-19 Monthly doses of glycopeptide antibiotics for treatment of streptococcus pneumoniae infections
IL14558200A IL145582A0 (en) 1999-05-03 2000-04-19 Monthly doses for treatment of streptococcus pneumoniae infections
AU43292/00A AU774647B2 (en) 1999-05-03 2000-04-19 Monthly doses for treatment of streptococcus pneumoniae infections
SK1557-2001A SK285970B6 (sk) 1999-05-03 2000-04-19 Použitie N DISACC-(4-(4-chlórfenyl)benzyl)A82846Balebo teikoplanínu na prípravu liečiva na dlhodobú prevenciu infekcií Streptococcus pneumoniae a farmaceutické kompozície s ich obsahom
NZ514467A NZ514467A (en) 1999-05-03 2000-04-19 Long-term prevention of streptococcus pneumonia infection with a monthly dose of NDISAcc-(4-(4-chlorophenyl) benzyl) A82846B or teicoplanin
UA2001117510A UA73937C2 (en) 1999-05-03 2000-04-19 Method of treatment for long-term prevention of s. pneumoniae in susceptible individuals and pharmaceutical composition for realizing this method
IL145582A IL145582A (en) 1999-05-03 2001-09-24 Use of NDISACC (4- (4-chlorophenyl) -benzyl) B82846A or tycoplanin, in the preparation of long-term treatment drugs for the prevention of streptococcal pneumoniae infections
NO20015291A NO20015291L (no) 1999-05-03 2001-10-29 Månedlige doser for behandling av Streptococcus pneumoniae- infeksjoner
HR20010808A HRP20010808A2 (en) 1999-05-03 2001-10-31 Monthly doses for treatment of streptococcus pneumoniae infections
HK02104765.3A HK1044707B (zh) 1999-05-03 2002-06-26 糖肽抗體用於長期預防肺炎鏈球菌感染的每月劑量

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13225899P 1999-05-03 1999-05-03
US60/132,258 1999-05-03

Publications (2)

Publication Number Publication Date
WO2000066144A2 WO2000066144A2 (fr) 2000-11-09
WO2000066144A3 true WO2000066144A3 (fr) 2001-04-12

Family

ID=22453188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008737 WO2000066144A2 (fr) 1999-05-03 2000-04-19 DOSES MENSUELLES DESTINEES AU TRAITEMENT DES INFECTIONS PAR $i(STREPTOCOCCUS PNEUMONIAE)

Country Status (29)

Country Link
EP (1) EP1175222B1 (fr)
JP (1) JP2002543146A (fr)
KR (1) KR100757165B1 (fr)
CN (1) CN1349407A (fr)
AR (1) AR023827A1 (fr)
AT (1) ATE284702T1 (fr)
AU (1) AU774647B2 (fr)
BR (1) BR0010244A (fr)
CA (1) CA2372790A1 (fr)
CZ (1) CZ296127B6 (fr)
DE (1) DE60016734T2 (fr)
DZ (1) DZ3039A1 (fr)
EA (1) EA004295B1 (fr)
HK (1) HK1044707B (fr)
HR (1) HRP20010808A2 (fr)
HU (1) HUP0200940A3 (fr)
IL (2) IL145582A0 (fr)
MY (1) MY123542A (fr)
NO (1) NO20015291L (fr)
NZ (1) NZ514467A (fr)
PE (1) PE20010292A1 (fr)
PL (1) PL353444A1 (fr)
SK (1) SK285970B6 (fr)
SV (1) SV2002000065A (fr)
TR (1) TR200103211T2 (fr)
TW (1) TWI255716B (fr)
UA (1) UA73937C2 (fr)
WO (1) WO2000066144A2 (fr)
ZA (1) ZA200108013B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013202360B2 (en) * 2008-08-30 2016-03-24 Melinta Therapeutics, Inc. Methods of treatment using single doses of oritavancin
EA020490B1 (ru) * 2008-08-30 2014-11-28 Тарганта Терапьютикс Корп. Способ лечения бактериальной инфекции
PL3038616T3 (pl) * 2013-08-26 2023-08-07 Melinta Therapeutics, Inc. Metody leczenia bakteriemii i zapalenia kości i szpiku z zastosowaniem orytawancyny

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GARCIA-GARROTE FERNANDO ET AL: "In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 42, no. 9, 1998, pages 2452 - 2455, XP002153843, ISSN: 0066-4804 *
JONES RONALD N ET AL: "In vitro activity and spectrum of LY333328, novel glycopeptide derivative.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 41, no. 2, 1997, pages 488 - 493, XP002153844, ISSN: 0066-4804 *
NICAS THALIA I ET AL: "Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 40, no. 9, 1996, pages 2194 - 2199, XP002153845, ISSN: 0066-4804 *
PATEL ROBIN ET AL: "In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.", DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, vol. 30, no. 2, February 1998 (1998-02-01), pages 89 - 92, XP000961191, ISSN: 0732-8893 *

Also Published As

Publication number Publication date
DZ3039A1 (fr) 2004-03-27
CZ20013949A3 (cs) 2002-07-17
TWI255716B (en) 2006-06-01
EP1175222A2 (fr) 2002-01-30
AU774647B2 (en) 2004-07-01
SK15572001A3 (sk) 2003-05-02
DE60016734T2 (de) 2005-12-08
AR023827A1 (es) 2002-09-04
EP1175222B1 (fr) 2004-12-15
HUP0200940A2 (en) 2002-08-28
HK1044707B (zh) 2005-09-30
CN1349407A (zh) 2002-05-15
CA2372790A1 (fr) 2000-11-09
SV2002000065A (es) 2002-12-02
CZ296127B6 (cs) 2006-01-11
WO2000066144A2 (fr) 2000-11-09
AU4329200A (en) 2000-11-17
HK1044707A1 (en) 2002-11-01
EA200101171A1 (ru) 2002-04-25
ZA200108013B (en) 2003-03-26
NZ514467A (en) 2005-01-28
EA004295B1 (ru) 2004-02-26
HRP20010808A2 (en) 2002-12-31
KR20020008173A (ko) 2002-01-29
TR200103211T2 (tr) 2002-02-21
DE60016734D1 (de) 2005-01-20
IL145582A (en) 2008-12-29
PL353444A1 (en) 2003-11-17
NO20015291L (no) 2001-12-17
PE20010292A1 (es) 2001-03-07
BR0010244A (pt) 2002-01-08
ATE284702T1 (de) 2005-01-15
MY123542A (en) 2006-05-31
NO20015291D0 (no) 2001-10-29
HUP0200940A3 (en) 2002-10-28
IL145582A0 (en) 2002-06-30
SK285970B6 (sk) 2007-12-06
KR100757165B1 (ko) 2007-09-07
JP2002543146A (ja) 2002-12-17
UA73937C2 (en) 2005-10-17

Similar Documents

Publication Publication Date Title
MY115351A (en) Pharmaceutical formulations
WO2000061115A3 (fr) Nouvelle methode de traitement
NZ552047A (en) Method of treatment of endobronchial infections
AUPQ890800A0 (en) Systems and apparatus for filling an injector syringe, and preventing patient infections
WO2001076575A3 (fr) Traitement de troubles respiratoires
WO2001082971A3 (fr) Compositions pharmaceutiques contenant un antibiotique glycopeptidique et une cyclodextrine
WO2000061116A3 (fr) Nouveau procede de traitement
CA2494015A1 (fr) Produit antibiotique, utilisation et formulation associees
NZ337246A (en) Pharmaceutical composition comprising amoxycillin and clavulanate
CA2349161A1 (fr) Preparation pharmaceutique de moxifloxacine
AU2001264021A1 (en) Luer-lock type sealing connection device for medical use, and syringe comprisingsame
MXPA05005338A (es) Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas.
HK1009101A1 (en) Use of a composition comprising amoxycillin and clavulanic acid for the manufacture of a medicament for the treatment of bacterial infections in paediatric patients
WO2005030109A3 (fr) Schema posologique pour l'administration d'antibiotiques de la classe des rifamycines
WO2002011694A3 (fr) Compositions et formes posologiques en vue d'une application dans la cavite orale dans le cadre du traitement de mycoses
WO2000012049A3 (fr) Methode de traitement d'une maladie staphylococcique
WO1997018790A3 (fr) Agents therapeutiques et de diagnostic pour traiter les infections microbiennes
AU2003290015A1 (en) Mastitis treatment
WO2000066144A3 (fr) DOSES MENSUELLES DESTINEES AU TRAITEMENT DES INFECTIONS PAR $i(STREPTOCOCCUS PNEUMONIAE)
AU2003268353A1 (en) Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
WO2003009859A1 (fr) Immunotherapie pour humains
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
DE69419782T2 (de) Multimeres alpha-lactalbumin enthaltende antibakterielle zusammensetzung
WO2002000839A3 (fr) Novispirines: peptides antimicrobiens
WO2000068258A3 (fr) Composes a action antibiotique

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200101062

Country of ref document: VN

Ref document number: 00807028.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 514467

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/1021/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 09958785

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 15572001

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2372790

Country of ref document: CA

Ref document number: 2372790

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20010808A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011161

Country of ref document: MX

Ref document number: 2001/03211

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PV2001-3949

Country of ref document: CZ

Ref document number: 1020017014017

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 615028

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000923113

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200101171

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020017014017

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000923113

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-3949

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2000923113

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV2001-3949

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1020017014017

Country of ref document: KR